Research at MD Anderson
Scroll Ahead
Research fuels our mission to end cancer
Many of the greatest minds in cancer research are at MD Anderson. They're here because MD Anderson offers a unique environment that accelerates their ability to end cancer. They collaborate with other cancer experts – in different research areas and with the world's leading cancer doctors. Bright students and trainees contribute further to our dynamic research environment. Discoveries are fueled by vast research support and resources. Tomorrow's medicine is available to our patients first since we have the most cancer clinical trials in the world. These research efforts work in parallel to fight cancer through prevention, early diagnosis, effective therapies and scientific breakthroughs.
2020 Research Publication Statistics
4,075
articles
154
editorials
543
reviews
Despite challenges—and a brief halt to in-person research—brought on by COVID-19, MD Anderson researchers contributed to over 4,700 total articles, editorials and reviews in 2020.
Departments, Labs and Institutes
MD Anderson has many parts, including departments, labs and institutes, but the sum of those parts is ending cancer. MD Anderson's reach is comprehensive when it comes to eliminating cancer.
Research Areas
Since 1941, MD Anderson has been home to some of the brightest minds across a variety of cancer research areas.
Resources
MD Anderson provides research tools and resources to fuel the discoveries of our scientists.
Moon Shots Program
Inspired by an unprecedented era of scientific discovery a generation ago, the Moon Shots Program® was launched by MD Anderson as an ambitious plan to make a giant leap in cancer research to benefit patients.
Learn more about the Moon Shots ProgramResearch Highlights
Hyperpolarized MRI
SCLC subtypes
Early detection
Mediterranean diet
Disease biology studies
CopyKAT
AML treatment
Nanomedicine research
NEWSROOM
Guillermina Lozano elected to Fellows of the AACR Academy
Guillermina (Gigi) Lozano, Ph.D., chair of Genetics, has been elected to the 2021 class of Fellows of the American Association for Cancer Research (AACR) Academy in recognition of her pioneering work to describe the p53 tumor suppressor pathway, which is undermined in many cancers.
Cancer clinical trials
How clinical trials advance innovative cancer care